MedTrace Logo

Effect Of Calcitriol On Neutrophil To Lymphocytes Ratio And High Sensitivity C-Reactive Protein Covid-19 Patients

NCT05765617 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2023-03-13

No results posted yet for this study

Summary

This research is a study that compares the administration of calcitriol with the outcomes of COVID-19 patients

Conditions

Interventions

DRUG

Calcitriol

The treatment group received calcitriol 2x400 iu per day for five days. Calcitriol uses Oscal, obtained from Kalbe Pharma

OTHER

Placebo

Placebo give 2x1 per day for five day

Sponsors & Collaborators

  • Universitas Sebelas Maret

    lead OTHER

Principal Investigators

  • Nurhasan Agung Prabowo, MD · Universitas Sebelas Maret

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-01
Primary Completion
2021-09-30
Completion
2021-09-30

Countries

  • Indonesia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05765617 on ClinicalTrials.gov